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Summary
Background Neurological and psychiatric sequelae of COVID-19 have been reported, but more data are needed to 
adequately assess the effects of COVID-19 on brain health. We aimed to provide robust estimates of incidence rates 
and relative risks of neurological and psychiatric diagnoses in patients in the 6 months following a COVID-19 diagnosis.
Methods For this retrospective cohort study and time-to-event analysis, we used data obtained from the TriNetX 
electronic health records network (with over 81 million patients). Our primary cohort comprised patients who had a 
COVID-19 diagnosis; one matched control cohort included patients diagnosed with influenza, and the other matched 
control cohort included patients diagnosed with any respiratory tract infection including influenza in the same period. 
Patients with a diagnosis of COVID-19 or a positive test for SARS-CoV-2 were excluded from the control cohorts. All 
cohorts included patients older than 10 years who had an index event on or after Jan 20, 2020, and who were still alive 
on Dec 13, 2020. We estimated the incidence of 14 neurological and psychiatric outcomes in the 6 months after a 
confirmed diagnosis of COVID-19: intracranial haemorrhage; ischaemic stroke; parkinsonism; Guillain-Barré 
syndrome; nerve, nerve root, and plexus disorders; myoneural junction and muscle disease; encephalitis; dementia; 
psychotic, mood, and anxiety disorders (grouped and separately); substance use disorder; and insomnia. Using a Cox 
model, we compared incidences with those in propensity score-matched cohorts of patients with influenza or other 
respiratory tract infections. We investigated how these estimates were affected by COVID-19 severity, as proxied by 
hospitalisation, intensive therapy unit (ITU) admission, and encephalopathy (delirium and related disorders). We 
assessed the robustness of the differences in outcomes between cohorts by repeating the analysis in different 
scenarios. To provide benchmarking for the incidence and risk of neurological and psychiatric sequelae, we compared 
our primary cohort with four cohorts of patients diagnosed in the same period with additional index events: skin 
infection, urolithiasis, fracture of a large bone, and pulmonary embolism. 
Findings Among 236 379 patients diagnosed with COVID-19, the estimated incidence of a neurological or psychiatric 
diagnosis in the following 6 months was 33·62% (95% CI 33·17–34·07), with 12·84% (12·36–13·33) receiving their 
first such diagnosis. For patients who had been admitted to an ITU, the estimated incidence of a diagnosis 
was 46·42% (44·78–48·09) and for a first diagnosis was 25·79% (23·50–28·25). Regarding individual diagnoses of 
the study outcomes, the whole COVID-19 cohort had estimated incidences of 0·56% (0·50–0·63) for intracranial 
haemorrhage, 2·10% (1·97–2·23) for ischaemic stroke, 0·11% (0·08–0·14) for parkinsonism, 0·67% (0·59–0·75) for 
dementia, 17·39% (17·04–17·74) for anxiety disorder, and 1·40% (1·30–1·51) for psychotic disorder, among others. 
In the group with ITU admission, estimated incidences were 2·66% (2·24–3·16) for intracranial haemorrhage, 6·92% 
(6·17–7·76) for ischaemic stroke, 0·26% (0·15–0·45) for parkinsonism, 1·74% (1·31–2·30) for dementia, 
19·15% (17·90–20·48) for anxiety disorder, and 2·77% (2·31–3·33) for psychotic disorder. Most diagnostic categories 
were more common in patients who had COVID-19 than in those who had influenza (hazard ratio [HR] 1·44, 95% CI 
1·40–1·47, for any diagnosis; 1·78, 1·68–1·89, for any first diagnosis) and those who had other respiratory tract 
infections (1·16, 1·14–1·17, for any diagnosis; 1·32, 1·27–1·36, for any first diagnosis). As with incidences, HRs were 
higher in patients who had more severe COVID-19 (eg, those admitted to ITU compared with those who were not: 
1·58, 1·50–1·67, for any diagnosis; 2·87, 2·45–3·35, for any first diagnosis). Results were robust to various sensitivity 
analyses and benchmarking against the four additional index health events.
Interpretation Our study provides evidence for substantial neurological and psychiatric morbidity in the 6 months 
after COVID-19 infection. Risks were greatest in, but not limited to, patients who had severe COVID-19. This 
information could help in service planning and identification of research priorities. Complementary study designs, 
including prospective cohorts, are needed to corroborate and explain these findings.
Funding National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license.
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Introduction
Since the COVID-19 pandemic began on March 11, 2020, 
there has been concern that survivors might be at an 
increased risk of neurological disorders. This concern, 
initially based on findings from other coronaviruses,1 
was followed rapidly by case series,2–4 emerging evidence 
of COVID-19 CNS involvement,5–7 and the identification 
of mechanisms by which this could occur.8–11 Similar 
concerns have been raised regarding psychiatric sequelae 
of COVID-19,12,13 with evidence showing that survivors 
are indeed at increased risk of mood and anxiety 
disorders in the 3 months after infection.14 However, we 
need large scale, robust, and longer term data to properly 
identify and quantify the consequences of the COVID-19 
pandemic on brain health. Such information is required 
both to plan services and identify research priorities.
In this study, we used an electronic health records 
network to investigate the incidence of neurological and 
psychiatric diagnoses in survivors in the 6 months after 
documented clinical COVID-19 infection, and we com-
pared the associated risks with those following other 
health conditions. We explored whether the severity of 
COVID-19 infection, as proxied by hos pitalisation, 
intensive therapy unit (ITU) admission, and enceph-
alopathy, affects these risks. We also assessed the 
trajectory of hazard ratios (HRs) across the 6-month 
period.
Methods
Study design and data collection
For this retrospective cohort study, we used The TriNetX 
Analytics Network, a federated network recording 
anonymised data from electronic health records in 
62 health-care organisations, primarily in the USA, 
comprising 81 million patients. Available data include 
demo graphics, diagnoses (using codes from ICD-10), 
medications, procedures, and measurements (eg, blood 
pressure and body-mass index). The health-care 
organisations are a mixture of hospitals, primary care, 
and specialist providers, contributing data from 
uninsured and insured patients. These organisations 
warrant that they have all necessary rights, consents, 
approvals, and authority to provide the data to TriNetX, 
so long as their name remains anonymous as a data 
source and their data are used for research purposes. By 
use of the TriNetX user interface, cohorts can be created 
on the basis of inclusion and exclusion criteria, matched 
for confounding variables with a built-in propensity 
score-matching algorithm, and compared for outcomes 
of interest over specified time periods. Additional details 
about TriNetX, its data, provenance, and functionalities, 
are presented in the appendix (pp 1–2).
Cohorts
The primary cohort was defined as all patients who had a 
confirmed diagnosis of COVID-19 (ICD-10 code U07.1). 
We also constructed two matched control cohorts: 
patients diagnosed with influenza (ICD-10 codes J09–11) 
and patients diagnosed with any respiratory tract 
infection including influenza (ICD-10 codes J00–06, 
J09–18, or J20–22). We excluded patients with a diagnosis 
of COVID-19 or a positive test for SARS-CoV-2 from the 
control cohorts. We refer to the diagnosis of COVID-19 
(in the primary cohort) and influenza or other respiratory 
See Online for appendix
For the TriNetX Analytics 
Network see www.trinetx.com
Research in context
Evidence before this study
We searched Web of Science and Medline on Aug 1 and 
Dec 31, 2020, for studies in English, with the terms “(COVID-19 
OR SARS-CoV2 OR SARS-CoV-2) AND (psychiatri* or 
neurologi*) AND (incidence OR epidemiologi* OR ‘systematic 
review’ or ‘meta-analysis’)”. We found case series and reviews of 
series reporting neurological and neuropsychiatric disorders 
during acute COVID-19 illness. We found one large electronic 
health records study of the psychiatric sequelae in the 3 months 
after a COVID-19 diagnosis. It reported an increased risk for 
anxiety and mood disorders and dementia after COVID-19 
compared with a range of other health events; the study also 
reported the incidence of each disorder. We are not aware of 
any large-scale data regarding the incidence or relative risks of 
neurological diagnoses in patients who had recovered from 
COVID-19.
Added value of this study
To our knowledge, we provide the first meaningful estimates of 
the risks of major neurological and psychiatric conditions in the 
6 months after a COVID-19 diagnosis, using the electronic 
health records of over 236 000 patients with COVID-19. 
We report their incidence and hazard ratios compared with 
patients who had had influenza or other respiratory tract 
infections. We show that both incidence and hazard ratios were 
greater in patients who required hospitalisation or admission to 
the intensive therapy unit (ITU), and in those who had 
encephalopathy (delirium and other altered mental states) 
during the illness compared with those who did not.
Implications of all the available evidence
COVID-19 was robustly associated with an increased risk of 
neurological and psychiatric disorders in the 6 months after a 
diagnosis. Given the size of the pandemic and the chronicity 
of many of the diagnoses and their consequences 
(eg, dementia, stroke, and intracranial haemorrhage), 
substantial effects on health and social care systems are likely 
to occur. Our data provide important evidence indicating the 
scale and nature of services that might be required. 
The findings also highlight the need for enhanced 
neurological follow-up of patients who were admitted to ITU 
or had encephalopathy during their COVID-19 illness.
Articles
418 www.thelancet.com/psychiatry   Vol 8   May 2021
tract infections (in the control cohorts) as index events. 
The cohorts included all patients older than 10 years who 
had an index event on or after Jan 20, 2020 (the date of 
the first recorded COVID-19 case in the USA), and who 
were still alive at the time of the main analysis 
(Dec 13, 2020). Additional details on cohorts are provided 
in the appendix (pp 2–3).
Covariates
We used a set of established and suspected risk factors for 
COVID-19 and for more severe COVID-19 illness:15,16 age, 
sex, race, ethnicity, obesity, hypertension, diabetes, chronic 
kidney disease, asthma, chronic lower respiratory 
diseases, nicotine dependence, substance use disorder, 
ischaemic heart disease and other forms of heart disease, 
socioeconomic deprivation, cancer (and haematological 
cancer in particular), chronic liver disease, stroke, 
dementia, organ transplant, rheumatoid arthritis, lupus, 
psoriasis, and disorders involving an immune mechanism. 
To capture these risk factors in patients’ health records, we 
used 55 variables. More details, including ICD-10 codes, 
are provided in the appendix (pp 3–4). Cohorts were 
matched for all these variables, as described in the 
following subsections.
Outcomes
We investigated neurological and psychiatric sequelae 
of COVID-19 in terms of 14 outcomes occurring 
1–180 days after the index event: intracranial 
haemorrhage (ICD-10 codes I60–62); ischaemic stroke 
(I63); Parkinson’s disease and parkinsonism (G20–21); 
Guillain-Barré syndrome (G61.0); nerve, nerve root, and 
plexus disorders (G50–59); myoneural junction and 
muscle disease (neuromuscular disorders; G70–73); 
encephalitis (G04, G05, A86, or A85.8); dementia 
(F01–03, G30, G31.0, or G31.83); psychotic, mood, and 
anxiety disorders (F20–48), as well as each category 
separately; substance use disorder (F10–19), and 
insomnia (F51.0 or G47.0).
For outcomes that are chronic illnesses (eg, dementia 
or Parkinson’s disease), we excluded patients who had 
the diagnosis before the index event. For outcomes that 








Cohort size 236 379 (100·0%) 190 077 (100·0%) 46 302 (100·0%) 8945 (100·0%) 6229 (100·0%)
Demographics
Age, years 46 (19·7) 43·3 (19·0) 57 (18·7) 59·1 (17·3) 66·7 (17·0)
Sex
Male 104 015 (44·0%) 81 512 (42·9%) 22 503 (48·6%) 5196 (58·1%) 3307 (53·1%)
Female 131 460 (55·6%) 107 730 (56·7%) 23 730 (51·3%) 3743 (41·8%) 2909 (46·7%)
Other 904 (0·4%) 835 (0·4%) 69 (0·1%) 10 (0·1%) 13 (0·2%)
Race
White 135 143 (57·2%) 109 635 (57·7%) 25 508 (55·1%) 4918 (55·0%) 3331 (53·5%)
Black or African American 44 459 (18·8%) 33 868 (17·8%) 10 591 (22·9%) 2184 (24·4%) 1552 (24·9%)
Unknown 48 085 (20·3%) 39 841 (21·0%) 8244 (17·8%) 1457 (16·3%) 1071 (17·2%)
Ethnicity
Hispanic or Latino 37 772 (16·0%) 29 155 (15·3%) 8617 (18·6%) 2248 (25·1%) 895 (14·4%)
Not Hispanic or Latino 134 075 (56·7%) 106 844 (56·2%) 27 231 (58·8%) 5041 (56·4%) 3873 (62·2%)
Unknown 64 532 (27·3%) 54 078 (28·5%) 10 454 (22·6%) 1656 (18·5%) 1461 (23·5%)
Comorbidities
Overweight and obesity 42 871 (18·1%) 30 198 (15·9%) 12 673 (27·4%) 3062 (34·2%) 1838 (29·5%)
Hypertensive disease 71 014 (30·0%) 47 516 (25·0%) 23 498 (50·7%) 5569 (62·3%) 4591 (73·7%)
Type 2 diabetes 36 696 (15·5%) 22 518 (11·8%) 14 178 (30·6%) 3787 (42·3%) 2890 (46·4%)
Asthma 25 104 (10·6%) 19 834 (10·4%) 5270 (11·4%) 1132 (12·7%) 755 (12·1%)
Nicotine dependence 17 105 (7·2%) 12 639 (6·6%) 4466 (9·6%) 1042 (11·6%) 803 (12·9%)
Substance use disorder 24 870 (10·5%) 18 173 (9·6%) 6697 (14·5%) 1620 (18·1%) 1316 (21·1%)
Ischaemic heart diseases 21 082 (8·9%) 11 815 (6·2%) 9267 (20·0%) 2460 (27·5%) 2200 (35·3%)
Other forms of heart 
disease
42 431 (18·0%) 26 066 (13·7%) 16 365 (35·3%) 4678 (52·3%) 3694 (59·3%)
Chronic kidney disease 15 908 (6·7%) 8345 (4·4%) 7563 (16·3%) 1941 (21·7%) 1892 (30·4%)
Neoplasms 45 255 (19·1%) 34 362 (18·1%) 10 893 (23·5%) 2339 (26·1%) 1793 (28·8%)
Data are n (%) or mean (SD). Only characteristics with a prevalence higher than 5% in the whole population are displayed. Additional baseline characteristics are presented in 
the appendix (pp 25–27). ITU=intensive therapy unit. 
Table 1: Baseline characteristics for the whole COVID-19 cohort and for the non-hospitalisation, hospitalisation, ITU admission, and encephalopathy 
cohorts during the illness 
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tend to recur or relapse (eg, ischaemic strokes or 
psychiatric diagnoses), we estimated separately the 
incidence of first diagnoses (ie, excluding those who 
had a diagnosis before the index event) and the 
incidence of any diagnosis (ie, including patients who 
had a diagnosis at some point before the index event). 
For other outcomes (eg, Guillain-Barré syndrome), we 
estimated the incidence of any diagnosis. More details, 
and a full list of ICD-10 codes, are provided in the 
appendix (pp 4–5).
Finally, to assess the overall risk of neurological and 
psychiatric outcomes after COVID-19, we estimated the 
incidence of any of the 14 outcomes, and the incidence of 
a first diagnosis of any of the outcomes. This is lower 
than the sum of incidences of each outcome because 
some patients had more than one diagnosis.
Secondary analyses
We investigated whether the neurological and psychiatric 
sequelae of COVID-19 were affected by the severity of the 
illness. The incidence of outcomes was estimated 
separately in four subgroups: first, in those who had 
required hospitalisation within a time window from 
4 days before their COVID-19 diagnosis (taken to be the 
time it might take between clinical presentation and 
confirmation) to 2 weeks afterwards; second, in those 
who had not required hospitalisation during that 
window; third, in those who had been admitted to an 
intensive therapy unit (ITU) during that window; 
and fourth, in those who were diagnosed with delirium 
or other forms of altered mental status during that 
window; we use the term encephalopathy to describe this 
group of patients (appendix p 5).17,18
Differences in outcome incidence between these 
subgroups might reflect differences in their baseline 
characteristics. Therefore, for each outcome, we 
estimated the HR between patients requiring hos-
pitalisation (or ITU) and a matched cohort of patients 
not requiring hospitalisation (or ITU), and between 
patients with encephalopathy and a matched cohort of 
patients without encephalopathy. Finally, HRs were 
calculated for patients who had not required hos-
pitalisation for COVID-19, influenza, or other 
respiratory tract infections.
To provide benchmarks for the incidence and risk of 
neurological and psychiatric sequelae, patients after 
COVID-19 were compared with those in four additional 
matched cohorts of patients diagnosed with health 
events selected to represent a range of acute 
presentations during the same time period. These 
additional four index events were skin infection, 
urolithiasis, fracture of a large bone, and pulmonary 
embolism. More details are presented in the 
appendix (pp 5–6).
We assessed the robustness of the differences in 
outcomes between cohorts by repeating the analysis in 
three scenarios: one including patients who had died by 



































































































































































































































































































Data are percentage at 6 months (95% CI). Additional outcomes are presented in the appendix (pp 27–28). 
ITU=intensive therapy unit.
Table 2: Major outcomes for the whole COVID-19 cohort, and for the non-hospitalisation, hospitalisation, 
ITU admission, and encephalopathy cohorts during the illness
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the time of the analysis, another restricting the COVID-19 
diagnoses to patients who had a positive RNA or antigen 
test (and using antigen test as an index event), and 
another comparing the rates of sequelae of patients with 
COVID-19 with those observed in patients with influenza 
before the pandemic (ie, in 2019 or 2018). Details of these 
analyses are provided in the appendix (p 6).
Finally, to test whether differences in sequelae between 
cohorts could be accounted for by differences in extent of 
follow-up, we counted the average number of health 
visits that each cohort had during the follow-up period.
Statistical analysis
We used propensity score matching19 to create cohorts 
with matched baseline characteristics, done within the 
TriNetX network. Propensity score with 1:1 matching 
used a greedy nearest neighbour matching approach 
with a calliper distance of 0·1 pooled SDs of the logit 
of the propensity score. Any characteristic with a 
standardised mean difference between cohorts lower 
than 0·1 was considered well matched.20 The incidence 
of each outcome was estimated by use of the Kaplan-
Meier estimator. Comparisons between cohorts were 
made with a log-rank test. We calculated HRs with 
95% CIs using a proportional hazard model wherein 
the cohort to which the patient belonged was used as 
the independent variable. The proportional hazard 
assumption was tested with the generalised Schoenfeld 
approach. When the assumption was violated, the time-
varying HR was assessed with natural cubic splines 
fitted to the log cumulative hazard.21 Additional details 
are presented in the appendix (p 6). Statistical analyses 
were done in R, version 3.4.3, except for the log-rank 
tests, which were done within TriNetX. Statistical 
significance was set at two-sided p-value <0⋅05. Our 
study was reported according to the Reporting of 
studies Conducted using Observational Routinely-
collected health Data (RECORD, appendix pp 55–60).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the manuscript.
Results
Our primary cohort comprised 236 379 patients 
diagnosed with COVID-19, and our two propensity-score-
matched control cohorts comprised 105 579 patients 
diagnosed with influenza and 236 038 patients diagnosed 
with any respiratory tract infection including influenza. 
The COVID-19 cohort was divided into subgroups of 
patients who were not hospitalised (190 077 patients), 
those who were hos pitalised (46 302 patients), those who 
required ITU admission (8945 patients), and those who 
received a diagnosis of encephalopathy (6229 patients). 
The main demographic features and comorbidities of the 
COVID-19 cohort are summarised in table 1, with 
additional demographic details presented in the 
appendix (pp 25–27). Matched baseline characteristics of 
the two control cohorts are also presented in the 
appendix (pp 29–30 for patients with influenza, and 
pp 31–32 for patients with other respiratory tract 
infections). Adequate propensity-score matching 
(standardised mean diff erence <0·1) was achieved for all 
comparisons and baseline characteristics.
We estimated the diagnostic incidence of the 
neurological and psychiatric outcomes of the primary 
cohort in the 6 months after a COVID-19 diagnosis. In 
the whole cohort, 33·62% (95% CI 33·17–34·07) 
of patients received a diagnosis (table 2). For the 
cohort subgroups, these estimates were 38·73% 
(37·87–39·60) for patients who were hospitalised, 
46·42% (44·78–48·09) for those admitted to ITU, and 
62·34% (60·14–64·55) for those diagnosed with 
COVID-19 vs influenza (N=105 579)* COVID-19 vs other RTI (N=236 038)*
HR (95% CI) p value HR (95% CI) p value
Intracranial haemorrhage 
(any)
2·44 (1·89–3·16) <0·0001 1·26 (1·11–1·43) 0·0003
Intracranial haemorrhage 
(first)
2·53 (1·68–3·79) <0·0001 1·56 (1·27–1·92) <0·0001
Ischaemic stroke (any) 1·62 (1·43–1·83) <0·0001 1·45 (1·36–1·55) <0·0001
Ischaemic stroke (first) 1·97 (1·57–2·47) <0·0001 1·63 (1·44–1·85) <0·0001
Parkinsonism 1·42 (0·75–2·67) 0·19 1·45 (1·05–2·00) 0·020
Guillain-Barré syndrome 1·21 (0·72–2·04) 0·41 2·06 (1·43–2·96) <0·0001
Nerve, nerve root, or 
plexus disorders
1·64 (1·50–1·81) <0·0001 1·27 (1·19–1·35) <0·0001
Myoneural junction or 
muscle disease
5·28 (3·71–7·53) <0·0001 4·52 (3·65–5·59) <0·0001
Encephalitis 1·70 (1·04–2·78) 0·028 1·41 (1·03–1·92) 0·028
Dementia 2·33 (1·77–3·07) <0·0001 1·71 (1·50–1·95) <0·0001
Mood, anxiety, or 
psychotic disorder (any)
1·46 (1·43–1·50) <0·0001 1·20 (1·18–1·23) <0·0001
Mood, anxiety, or 
psychotic disorder (first)
1·81 (1·69–1·94) <0·0001 1·48 (1·42–1·55) <0·0001
Mood disorder (any) 1·47 (1·42–1·53) <0·0001 1·23 (1·20–1·26) <0·0001
Mood disorder (first) 1·79 (1·64–1·95) <0·0001 1·41 (1·33–1·50) <0·0001
Anxiety disorder (any) 1·45 (1·40–1·49) <0·0001 1·17 (1·15–1·20) <0·0001
Anxiety disorder (first) 1·78 (1·66–1·91) <0·0001 1·48 (1·42–1·55) <0·0001
Psychotic disorder (any) 2·03 (1·78–2·31) <0·0001 1·66 (1·53–1·81) <0·0001
Psychotic disorder (first) 2·16 (1·62–2·88) <0·0001 1·82 (1·53–2·16) <0·0001
Substance use disorder 
(any)
1·27 (1·22–1·33) <0·0001 1·09 (1·05–1·12) <0·0001
Substance use disorder 
(first)
1·22 (1·09–1·37) 0·0006 0·92 (0·86–0·99) 0·033
Insomnia (any) 1·48 (1·38–1·57) <0·0001 1·15 (1·10–1·20) <0·0001
Insomnia (first) 1·92 (1·72–2·15) <0·0001 1·43 (1·34–1·54) <0·0001
Any outcome 1·44 (1·40–1·47) <0·0001 1·16 (1·14–1·17) <0·0001
Any first outcome 1·78 (1·68–1·89) <0·0001 1·32 (1·27–1·36) <0·0001
Additional details on cohort characteristics and diagnostic subcategories are presented in the appendix (pp 29–33). 
HR=hazard ratio. RTI=respiratory tract infection. *Matched cohorts. 
Table 3: HRs for the major outcomes in patients after COVID-19 compared with those after influenza and 
other RTIs
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encephalopathy. A similar, but more marked, increasing 
trend was observed for patients receiving their first 
recorded neurological or psychiatric diagnosis (table 2). 
Results according to sex, race, and age are shown in the 
appendix (p 28). The baseline characteristics of the 
COVID-19 cohort divided into those who did versus 
those who did not have a neurological or psychiatric 
outcome are also shown in the appendix (p 7).
We assessed the probability of the major neurological 
and psychiatric outcomes in patients diagnosed with 
COVID-19 compared with the matched cohorts 
diagnosed with other respiratory tract infections and 
with influenza (table 3; figure 1, appendix pp 8–10). Most 
diagnostic categories were more common in patients 
who had COVID-19 than in those who had influenza 
(HR 1·44, 95% CI 1·40–1·47 for any diagnosis; 
1·78, 1·68–1·89 for any first diagnosis) and those who 
had other respiratory tract infections (1·16, 1·14–1·17 for 
any diagnosis; 1·32, 1·27–1·36 for any first diagnosis). 
Hazard rates were also higher in patients who were 
admitted to ITU than in those who were not 
(1·58, 1·50–1·67 for any diagnosis; 2·87, 2·45–3·35 for 
any first diagnosis). HRs were significantly greater than 
1 for all diagnoses for patients who had COVID-19 
compared with those who had influenza, except for 
parkinsonism and Guillain-Barré syndrome, and 
significantly greater than 1 for all diagnoses compared 
with patients who had respiratory tract infections 
(table 3). Similar results were observed when patients 
who had COVID-19 were compared with those who had 
Figure 1: Kaplan-Meier estimates for the incidence of major outcomes after COVID-19 compared with other RTIs
Shaded areas are 95% CIs. For incidences of first diagnoses, the number in brackets corresponds to all patients who did not have the outcome before the follow-up period. For diagnostic subcategories, 
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one of the four other index events (appendix pp 11–14, 34), 
except when an outcome had a predicted relationship 
with the comparator condition (eg, intracranial 
haem orrhage was more common in association with 
fracture of a large bone). HRs for diag nostic 
subcategories are presented in the appendix (p 33).
There were no violations of the proportional hazards 
assumption for most of the neurological outcomes over 
the 6 months of follow-up (appendix pp 15, 35). The only 
exception was for intracranial haemorrhage and 
ischaemic stroke in patients who had COVID-19 when 
compared with patients who had other respiratory tract 
infections (p=0·012 for intracranial haemorrhage and 
p=0·032 for ischaemic stroke). For the overall psychiatric 
disorder category (ICD-10 F20–48), the HR did vary with 
time, declining but remaining significantly higher than 1, 
indicating that the risk was attenuated but maintained 
6 months after COVID-19 diagnosis (appendix p 9). HRs 
for COVID-19 diagnosis compared with the additional 
four index events showed more variation with time, 
partly reflecting the natural history of the comparator 
condition (appendix, pp 16–19, 36).
We explored the effect of COVID-19 severity 
in four ways. First, we restricted analyses to matched 
cohorts of patients who had not required hos-
pitalisation (matched baseline characteristics in the 
appendix, pp 37–40). HRs remained significantly greater 
than 1 in this subgroup, with an overall HR for any 
diagnosis of 1·47 (95% CI 1·44–1·51) for patients who 
had COVID-19 compared with patients who had 
influenza, and 1·16 (1·14–1·17) compared with those who 
had other respiratory tract infections (table 4, 
appendix pp 20–21). For a first diagnosis, the HRs 
were 1·83 (1·71–1·96) versus patients who had influenza 
and 1·28 (1·23–1·33) versus those who had other 
respiratory tract infections. Second, we calculated HRs 
for the matched cohorts of patients with COVID-19 
requiring hospitalisation versus those who did not 
require hospitalisation (44 927 matched patients; 
matched baseline characteristics are presented in the 
appendix, pp 41–42). This comparison showed greater 
hazard rates for all outcomes in the hospitalised group 
than in the non-hospitalised group, except for nerve, 
nerve root, or plexus disorders (table 5, figure 2), with an 
overall HR of 1·33 (1·29–1·37) for any diagnosis and 
1·70 (1·56–1·86) for any first diagnosis. Third, we 
calculated HRs for the matched cohorts of patients with 
COVID-19 requiring ITU admission versus those not 
COVID-19 vs influenza in patients without 
hospitalisation (N=96 803)*
COVID-19 vs other RTI in patients without 
hospitalisation (N=183 731)*
HR (95% CI) p value HR (95% CI) p value
Intracranial haemorrhage (any) 1·87 (1·25–2·78) 0·0013 1·38 (1·11–1·73) 0·0034
Intracranial haemorrhage (first) 1·66 (0·88–3·14) 0·082 1·63 (1·11–2·40) 0·010
Ischaemic stroke (any) 1·80 (1·54–2·10) <0·0001 1·61 (1·45–1·78) <0·0001
Ischaemic stroke (first) 1·71 (1·26–2·33) 0·0003 1·69 (1·38–2·08) <0·0001
Parkinsonism 2·22 (0·98–5·06) 0·028 1·20 (0·73–1·96) 0·42
Guillain-Barré syndrome 0·90 (0·44–1·84) 0·99 1·44 (0·85–2·45) 0·10
Nerve, nerve root, or plexus disorders 1·69 (1·53–1·88) <0·0001 1·23 (1·15–1·33) <0·0001
Myoneural junction or muscle disease 3·46 (2·11–5·67) <0·0001 2·69 (1·91–3·79) <0·0001
Encephalitis 1·77 (0·86–3·66) 0·095 2·29 (1·28–4·10) 0·0046
Dementia 1·88 (1·27–2·77) 0·0008 1·95 (1·55–2·45) <0·0001
Mood, anxiety, or psychotic disorder (any) 1·49 (1·45–1·54) <0·0001 1·18 (1·15–1·21) <0·0001
Mood, anxiety, or psychotic disorder (first) 1·85 (1·72–1·99) <0·0001 1·40 (1·32–1·48) <0·0001
Mood disorder (any) 1·49 (1·43–1·55) <0·0001 1·22 (1·19–1·26) <0·0001
Mood disorder (first) 1·78 (1·61–1·96) <0·0001 1·37 (1·27–1·47) <0·0001
Anxiety disorder (any) 1·48 (1·43–1·54) <0·0001 1·16 (1·13–1·19) <0·0001
Anxiety disorder (first) 1·80 (1·67–1·94) <0·0001 1·37 (1·30–1·45) <0·0001
Psychotic disorder (any) 1·93 (1·63–2·28) <0·0001 1·44 (1·27–1·62) <0·0001
Psychotic disorder (first) 2·27 (1·56–3·30) <0·0001 1·49 (1·15–1·93) 0·0016
Substance use disorder (any) 1·26 (1·19–1·33) <0·0001 1·11 (1·07–1·17) <0·0001
Substance use disorder (first) 1·21 (1·05–1·38) 0·0054 0·89 (0·81–0·97) 0·013
Insomnia (any) 1·52 (1·42–1·63) <0·0001 1·18 (1·12–1·24) <0·0001
Insomnia (first) 2·06 (1·82–2·33) <0·0001 1·51 (1·38–1·66) <0·0001
Any outcome 1·47 (1·44–1·51) <0·0001 1·16 (1·14–1·17) <0·0001
Any first outcome 1·83 (1·71–1·96) <0·0001 1·28 (1·23–1·33) <0·0001
Details on cohort characteristics are presented in the appendix (pp 37–40). HR=hazard ratio. RTI=respiratory tract infection. *Matched cohorts. 
Table 4: HRs for the major outcomes in patients without hospitalisation after COVID-19 compared with those after influenza or other RTIs 
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requiring ITU admission (8942 patients; matched baseline 
characteristics presented in the appendix, pp 43–44), 
with a HR of 1·58 (1·50–1·67) for any diagnosis 
and 2·87 (2·45–3·35) for any first diagnosis (table 5, 
appendix p 22). Fourth, we calculated HRs for the 
matched cohorts of patients with COVID-19 who had 
encephalopathy diagnosed during acute illness versus 
those who did not (6221 patients; matched baseline 
characteristics presented in the appendix, pp 45–46). 
HRs for all diagnoses were greater for the group who had 
encephalopathy than for the matched cohort who did 
not, with an overall HR of 1·85 (1·73–1·98) for any 
diagnosis and 3·19 (2·54–4·00) for any first diagnosis 
(table 5, figure 2).
We inspected other factors that might influence the 
findings. The results regarding hospitalisation, ITU 
admission, or encephalopathy (which we had defined as 
occurring up to 14 days after diagnosis) could be 
confounded by admissions due to an early complication 
of COVID-19 rather than to COVID-19 itself. This was 
explored by excluding outcomes during this period, with 
the findings remaining similar, albeit with many HRs 
being reduced (appendix pp 47–49). Additionally, 
COVID-19 survivors had fewer health-care visits during 
the 6-month period compared with the other cohorts 
(appendix p 50). Hence the higher incidence of many 
diagnoses was not simply due to having had more 
diagnostic opportunities.
The increased rates of neurological and psychiatric 
sequelae were robust in all three sensitivity analyses: 
when patients who had died by the time of the analysis 
were included (appendix p 51), when the COVID-19 
diagnosis was confirmed by use of an RNA or antigen 
test (appendix p 52), and when the sequelae were 
compared with those observed in patients who had 
influenza in 2019 or 2018 (appendix pp 53).
Discussion
Various adverse neurological and psychiatric outcomes 
occurring after COVID-19 have been predicted and 
COVID-19 with vs without 
hospitalisation (N=45 167)
COVID-19 with vs without ITU 
admission (N=8942)
COVID-19 with vs without 
encephalopathy (N=6221)
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Intracranial haemorrhage (any) 3·09 (2·43–3·94) <0·0001 5·06 (3·43–7·47) <0·0001 4·73 (3·15–7·11) <0·0001
Intracranial haemorrhage (first) 3·75 (2·49–5·64) <0·0001 5·12 (2·68–9·77) <0·0001 5·00 (2·33–10·70) <0·0001
Ischaemic stroke (any) 1·65 (1·48–1·85) <0·0001 1·93 (1·62–2·31) <0·0001 1·65 (1·38–1·97) <0·0001
Ischaemic stroke (first) 2·82 (2·22–3·57) <0·0001 3·51 (2·39–5·15) <0·0001 3·39 (2·17–5·29) <0·0001
Parkinsonism 2·63 (1·45–4·77) 0·0016 3·90 (1·29–11·79) 0·024 1·64 (0·75–3·58) 0·24
Guillain-Barré syndrome 2·94 (1·60–5·42) 0·00094 11·01 (2·55–47·61) 0·0007 2·27 (0·76–6·73) 0·24
Nerve, nerve root, or plexus 
disorders
0·94 (0·83–1·06) 0·29 1·16 (0·92–1·45) 0·21 1·41 (1·07–1·87) 0·018
Myoneural junction or muscle 
disease
7·76 (5·15–11·69) <0·0001 11·53 (6·38–20·83) <0·0001 5·40 (3·21–9·07) <0·0001
Encephalitis 3·26 (1·75–6·06) 0·0002 1·78 (0·75–4·20) 0·22 9·98 (2·98–33·43) <0·0001
Dementia 2·28 (1·80–2·88) <0·0001 1·66 (1·12–2·46) 0·018 4·25 (2·79–6·47) <0·0001
Mood, anxiety, or psychotic 
disorder (any)
1·23 (1·18–1·28) <0·0001 1·34 (1·24–1·46) <0·0001 1·73 (1·58–1·90) <0·0001
Mood, anxiety, or psychotic 
disorder (first)
1·55 (1·40–1·71) <0·0001 2·27 (1·87–2·74) <0·0001 2·28 (1·80–2·89) <0·0001
Mood disorder (any) 1·21 (1·15–1·28) <0·0001 1·15 (1·03–1·27) 0·010 1·51 (1·35–1·70) <0·0001
Mood disorder (first) 1·53 (1·33–1·75) <0·0001 2·06 (1·57–2·71) <0·0001 2·09 (1·55–2·80) <0·0001
Anxiety disorder (any) 1·16 (1·10–1·22) <0·0001 1·39 (1·26–1·53) <0·0001 1·64 (1·45–1·84) <0·0001
Anxiety disorder (first) 1·49 (1·34–1·65) <0·0001 2·22 (1·82–2·71) <0·0001 1·91 (1·48–2·45) <0·0001
Psychotic disorder (any) 2·22 (1·92–2·57) <0·0001 1·48 (1·14–1·92) 0·0028 3·84 (2·90–5·10) <0·0001
Psychotic disorder (first) 2·77 (1·99–3·85) <0·0001 1·77 (0·98–3·20) 0·072 5·62 (2·93–10·77) <0·0001
Substance use disorder (any) 1·53 (1·42–1·64) <0·0001 1·62 (1·41–1·85) <0·0001 1·45 (1·24–1·70) <0·0001
Substance use disorder (first) 1·68 (1·40–2·01) <0·0001 2·53 (1·83–3·50) <0·0001 2·03 (1·32–3·11) 0·0015
Insomnia (any) 1·08 (0·99–1·18) 0·088 1·40 (1·19–1·66) <0·0001 1·73 (1·42–2·11) <0·0001
Insomnia (first) 1·49 (1·28–1·74) <0·0001 1·93 (1·46–2·55) <0·0001 3·44 (2·35–5·04) <0·0001
Any outcome 1·33 (1·29–1·37) <0·0001 1·58 (1·50–1·67) <0·0001 1·85 (1·73–1·98) <0·0001
Any first outcome 1·70 (1·56–1·86) <0·0001 2·87 (2·45–3·35) <0·0001 3·19 (2·54–4·00) <0·0001
Details on cohort characteristics are presented in the appendix (pp 41–46). HR=hazard ratio. ITU=intensive therapy unit. *Matched cohorts. 
Table 5: HRs for the major outcomes after COVID-19 for patients with vs those without hospitalisation, patients with vs without ITU admission, 
and patients with vs without encephalopathy
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reported.1–5,14 The data presented in this study, from a 
large electronic health records network, support these 
predictions and provide estimates of the incidence and 
risk of these outcomes in patients who had COVID-19 
compared with matched cohorts of patients with other 
health conditions occurring contemporaneously with the 
COVID-19 pandemic (tables 2, 3, figure 1).
The severity of COVID-19 had a clear effect on 
subsequent neurological diagnoses (tables 4, 5, 
figure 2). Overall, COVID-19 was associated with 
increased risk of neurological and psychiatric outcomes, 
but the incidences and HRs of these were greater in 
patients who had required hospitalisation, and 
markedly so in those who had required ITU admission 
or had developed encephalopathy, even after extensive 
propensity score matching for other factors 
(eg, age or previous cerebrovascular disease). Potential 
mechanisms for this association include viral invasion 
of the CNS,10,11 hypercoagulable states,22 and neural 
effects of the immune response.9 However, the 
incidence and relative risk of neurological and 
psychiatric diagnoses were also increased even in 
patients with COVID-19 who did not require 
hospitalisation.
Some specific neurological diagnoses merit individual 
mention. Consistent with several other reports,23,24 the 
risk of cerebrovascular events (ischaemic stroke and 
intracranial haemorrhage) was elevated after COVID-19, 
with the incidence of ischaemic stroke rising to almost 
one in ten (or three in 100 for a first stroke) in patients 
with encephalopathy. A similarly increased risk of 
stroke in patients who had COVID-19 compared with 
those who had influenza has been reported.25 Our 
previous study reported preliminary evidence for an 
association between COVID-19 and dementia.14 The 
data in this study support this association. Although 
the estimated incidence was modest in the whole 
COVID-19 cohort (table 2), 2·66% of patients older 
than 65 years (appendix p 28) and 4·72% who had 
encephalopathy (table 2), received a first diagnosis of 
dementia within 6 months of having COVID-19. The 
associations between COVID-19 and cerebrovascular 
and neurodegenerative diagnoses are concerning, and 
information about the severity and subsequent course 
of these diseases is required.
Whether COVID-19 is associated with Guillain-Barré 
syndrome remains unclear;26 our data were also 
equivocal, with HRs increased with COVID-19 compared 
with other respiratory tract infections but not with 
influenza (table 3), and increased compared with three of 
the four other index health events (appendix p 34). 
Concerns have also been raised about post-COVID-19 
parkinsonian syndromes, driven by the encephalitis 
lethargica epidemic that followed the 1918 influenza 
pandemic.27 Our data provide some support for this 
possibility, although the incidence was low and not all 
HRs were significant. Parkinsonism might be a delayed 
outcome, in which case a clearer signal might emerge 
with a longer follow-up.
The findings regarding anxiety and mood disorders 
were broadly consistent with 3-month outcome data 
from a study done in a smaller number of cases than 
our cohort, using the same network,14 and showed that 
the HR remained elevated, although decreasing, at the 
6-month period. Unlike the earlier study, and in line 
with previous suggestions,28 we also observed a 
significantly increased risk of psychotic disorders, 
probably reflecting the larger sample size and longer 
duration of follow-up reported here. Substance use 
disorders and insomnia were also more common in 
COVID-19 survivors than in those who had influenza or 
other respiratory tract infections (except for the 
incidence of a first diagnosis of substance use disorder 
after COVID-19 compared with other respiratory tract 
infections). Therefore, as with the neurological 
outcomes, the psychiatric sequelae of COVID-19 appear 
widespread and to persist up to, and probably beyond, 
6 months. Compared with neurological disorders, 
common psychiatric disorders (mood and anxiety 
disorders) showed a weaker relationship with the 
markers of COVID-19 severity in terms of incidence 
(table 2) or HRs (table 5). This might indicate that their 
occurrence reflects, at least partly, the psychological 
and other implications of a COVID-19 diagnosis rather 
than being a direct manifestation of the illness.
HRs for most neurological outcomes were constant, 
and hence the risks associated with COVID-19 persisted 
up to the 6-month timepoint. Longer-term studies are 
needed to ascertain the duration of risk and the trajectory 
for individual diagnoses.
Our findings are robust given the sample size, the 
propensity score matching, and the results of the 
sensitivity and secondary analyses. Nevertheless, they 
have weaknesses inherent to an electronic health 
records study,29 such as the unknown completeness of 
records, no validation of diagnoses, and sparse 
information on socioeconomic and lifestyle factors. 
These issues primarily affect the incidence estimates, 
but the choice of cohorts against which to compare 
COVID-19 outcomes influenced the magnitude of the 
HRs (table 3, appendix p 34). The analyses regarding 
encephalopathy (delirium and related conditions) 
deserve a note of caution. Even among patients who 
were hospitalised, only about 11% received this 
Figure 2: Kaplan-Meier estimates for the incidence of major outcomes after 
COVID-19 comparing patients requiring hospitalisation with matched 
patients not requiring hospitalisation, and comparing those who had 
encephalopathy with matched patients who did not have encephalopathy
95% CIs are omitted for clarity but are shown in the appendix (p 23). 
For incidences of first diagnoses, the total number corresponds to all patients 
who did not have the outcome before the follow-up period. The equivalent 
figure showing the comparison between patients with intensive therapy unit 
admission versus those without is presented in the appendix (p 22).
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diagnosis, whereas much higher rates would be 
expected.18,30 Under-recording of delirium during acute 
illness is well known and probably means that the 
diagnosed cases had prominent or sustained features; 
as such, results for this group should not be generalised 
to all patients with COVID-19 who experience delirium. 
We also note that encephalopathy is not just a severity 
marker but a diagnosis in itself, which might predispose 
to, or be an early sign of, other neuro psychiatric or 
neurodegenerative outcomes observed during follow-
up. The timing of index events was such that most 
infections with influenza and many of the other 
respiratory tract infections occurred earlier on during 
the pandemic, whereas the incidence of COVID-19 
diagnoses increased over time (appendix p 24). The 
effect of these timing differences on observed rates of 
sequelae is unclear but, if anything, they are likely to 
make the HRs an underestimate because COVID-19 
cases were diagnosed at a time when all other diagnoses 
were made at a lower rate in the population 
(appendix p 24). Some patients in the comparison 
cohorts are likely to have had undiagnosed COVID-19; 
this would also tend to make our HRs an underestimate. 
Finally, a study of this kind can only show associations; 
efforts to identify mechanisms and assess causality will 
require prospective cohort studies and additional study 
designs.
In summary, the present data show that COVID-19 
is followed by significant rates of neurological and psy-
chiatric diagnoses over the subsequent 6 months. 
Services need to be configured, and resourced, to deal 
with this anticipated need.
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